Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis

BACKGROUND: The epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This meta-analysis compared their effectiveness and safety. METHODS: We searched systematically in PubMed, ScienceDirect, The Cochrane Li...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenxiong, Wei, Yiping, Yu, Dongliang, Xu, Jianjun, Peng, Jinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916648/
https://www.ncbi.nlm.nih.gov/pubmed/29668619
http://dx.doi.org/10.1097/MD.0000000000010460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916648/
https://www.ncbi.nlm.nih.gov/pubmed/29668619
http://dx.doi.org/10.1097/MD.0000000000010460

Ejemplares similares